Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 9, 2009

FDA Notifies Spectrum that Its sNDA Does Not Support Fusilev Approval in Colorectal Cancer

  • FDA has issued Spectrum Pharmaceuticals a complete response letter stating that the sNDA for Fusilev did not demonstrate that it was “noninferior” to leucovorin in treating advanced metastatic colorectal cancer. The company will request a meeting with the agency to discuss options for Fusilev in this indication.

    Spectrum’s drug, a novel folate analog, is already sanctioned for use after high-dose methotrexate therapy in osteosarcoma. It is also approved to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists. It is available in vials as freeze-dried powder. The firm’s sNDA covered Fusilev for injection as a treatment for patients with advanced metastatic colorectal cancer.

    Leucovorin, a folic acid analog, is also approved to prevent harmful effects of methotrexate when used in certain cancers and to treat people who have accidentally received an overdose of methotrexate or similar medications.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »